Evidence map›Paper›PMID 21415415›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2011

Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Alexander A Chumanevich, Corey P Causey, Bryan A Knuckley, Justin E Jones, Deepak Poudyal, Alena P Chumanevich, Tia Davis, Lydia E Matesic, Paul R Thompson, Lorne J Hofseth

Abstract readVideo-Audio Media
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 201 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Acta pharmaceutica Sinica. B · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic Apheresis.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2025
    Review
  18. Article
  19. Review
  20. Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alexander A ChumanevichDepartment of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, 29208, USA.
Corey P Causey
Bryan A Knuckley
Justin E Jones
Deepak Poudyal
Alena P Chumanevich
Tia Davis
Lydia E Matesic
Paul R Thompson
Lorne J Hofseth
Scripps Research Institute · USUniversity of South Carolina · US

Funding

TISSUE BIOREPOSITORYP20RR017698 · NCRR · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI FAYAD, RAJA · 2002 to 2011
$22.5M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2007 to 2018
$14.2M
Haloacetamidine based inactivators of Protein Arginine Deiminase 4R01GM079357 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI THOMPSON, PAUL R · 2007 to 2016
$3.3M
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon CancerR01CA151304 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HOFSETH, LORNE J, THOMPSON, PAUL R · 2011 to 2015
$1.6M
NCCIH NIH HHS P01 AT003961NCI NIH HHS 1R01CA151304NCI NIH HHS 1R01CA151304-01A1NCI NIH HHS R01 CA151304NCRR NIH HHS 5P20 RR-017698-08NCRR NIH HHS P20 RR017698NIGMS NIH HHS GM-079357
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBDs), mainly Crohn's disease and ulcerative colitis, are dynamic, chronic inflammatory conditions that are associated with an increased colon cancer risk. Inflammatory cell apoptosis is a key mechanism for regulating IBD. Peptidylarginine deiminases (PADs) catalyze the posttranslational conversion of peptidylarginine to peptidylcitrulline in a calcium-dependent, irreversible reaction and mediate the effects of proinflammatory cytokines. Because PAD levels are elevated in mouse and human colitis, we hypothesized that a novel small-molecule inhibitor of the PADs, i.e., chloramidine (Cl-amidine), could suppress colitis in a dextran sulfate sodium mouse model. Results are consistent with this hypothesis, as demonstrated by the finding that Cl-amidine treatment, both prophylactic and after the onset of disease, reduced the clinical signs and symptoms of colitis, without any indication of toxic side effects. Interestingly, Cl-amidine drives apoptosis of inflammatory cells in vitro and in vivo, providing a mechanism by which Cl-amidine suppresses colitis. In total, these data help validate the PADs as therapeutic targets for the treatment of IBD and further suggest Cl-amidine as a candidate therapy for this disease.

Indexed as

Administration, OralAnimalsAnti-Inflammatory AgentsApoptosisArginineCitrullineColitisColonDextran SulfateDisease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsGastrointestinal AgentsHT29 CellsHumansHydrolasesAnti-Inflammatory AgentsArginineCitrullineDextran SulfateEnzyme InhibitorsGastrointestinal AgentsHydrolasesN-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amideOrnithineProtein-Arginine Deiminases

Identifiers

PMID21415415
PMCPMC3119113
OpenAlexW2097957649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.